Assessment of candidate biomarkers for neuromyelitis optica spectrum disorder

Takeaway

  • CD16+/CD56+ NK cells and CX3CL1 were identified as potential biomarkers for neuromyelitis optica spectrum disorder (NMSOD).

Why this matters

    Previously identified autoantibody biomarker candidates have not been able to convincingly predict relapses, therapy response or prognosis.